-+ 0.00%
-+ 0.00%
-+ 0.00%

Alpha Tau, Tolmar partner to develop, commercialize Alpha DaRT for U.S. prostate cancer patients

PUBT·06/03/2026 12:33:50
Listen to the news
Alpha Tau, Tolmar partner to develop, commercialize Alpha DaRT for U.S. prostate cancer patients
  • Alpha Tau Medical entered a strategic collaboration with Tolmar to develop and commercialize Alpha DaRT for U.S. prostate cancer.
  • Tolmar gets exclusive U.S. commercialization rights for prostate cancer for about 20 years from first sale.
  • Tolmar invested USD 20 million in equity at USD 11.99 a share; paid USD 15 million toward a new U.S. production facility.
  • Deal includes up to USD 161.5 million in clinical, regulatory, and commercial milestones for the first indication.
  • Alpha Tau will manufacture and supply product at 60% of onward net sales; Tolmar holds a bladder cancer option tied to criteria.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030830PRIMZONEFULLFEED9731177) on June 03, 2026, and is solely responsible for the information contained therein.